BioSpace News Archive

Biovation Labs, a leading supplement contract manufacturer, today announced it is expanding its capabilities to better serve its clients with the installation of an Aquarius G-J high speed rotary tablet press from Kikusui.

BREVENA Laboratories, LLC, a luxury skin care cosmetics company, announces the addition of Skin Expert and Advanced Practice Esthetician, Susannah Courteau to their leadership and advisory team.

Physicians’ Education Resource® (PER®), the nation’s leading resource for oncology and hematology continuing medical education (CME), will host its second annual Precision Medicine Through Plasma: Using Liquid Biopsies in Contemporary Oncology Care workshop on Saturday, Dec. 8 at the Convene in New York City.

As part of its mission to advance health equity in Minnesota, the Center for Prevention at Blue Cross and Blue Shield of Minnesota has released a podcast series, “The State We’re In,” where they investigate what it means to have fair and just opportunities to be healthy.

First dose of potential treatment AT-1501 given to humans by Anelixis Therapeutics to determine safety and tolerability

Qosina is pleased to announce the launch of its newly redesigned e-commerce website.

WuXi Biologics (2269.HK, WuXi Bio), and ABL Bio Corporation (ABL Bio), today announced that the companies have entered into an exclusive development and clinical manufacturing partnership for up to 8 antibody therapeutics including ABL Bio’s biologics pipelines and collaboration programs between ABL Bio and I-Mab Biopharma (I-Mab).

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce the appointment of Dr Joseph D Khoury as a Scientific Advisor to the Company’s established Scientific Advisory Board.

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for an expanded label for gammaCore™ [non-invasive vagus nerve stimulator (nVNS)] therapy for adjunctive use for the preventive treatment of cluster headache in adult patients.

Food and Drug Administration (FDA) today approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL) to be used as a single agent or in combination with chemotherapy